Tamiflu

Tamiflu
BartVL71 · Public domain · source
Name	Tamiflu
Generic name	oseltamivir phosphate
Tradename	Tamiflu
Routes of administration	oral
Class	neuraminidase inhibitor
Legal status	prescription-only in many countries

Tamiflu is the trade name for oseltamivir phosphate, an antiviral medication primarily used for treatment and prophylaxis of influenza A and B infections. Developed through collaborations among pharmaceutical companies and research institutions, Tamiflu became a focus of public health planning during seasonal epidemics and pandemic preparedness efforts. It has been subject to extensive clinical evaluation, regulatory review, and public debate involving governments, agencies, and academic centers.

Medical uses

Tamiflu is indicated for treatment of uncomplicated influenza in adults and children and for prevention of influenza in exposed populations, with recommendations issued by agencies such as the World Health Organization, Centers for Disease Control and Prevention, European Medicines Agency, Health Canada, and national health ministries. Clinical use targets high-risk groups identified by organizations like American Academy of Pediatrics and National Institute for Health and Care Excellence, including elderly residents of long-term care facilities, immunocompromised patients seen at tertiary centers, and pregnant persons managed in obstetric services. Public health deployment during events such as the 2009 flu pandemic involved stockpiles managed by ministries and agencies including the United States Department of Health and Human Services and the National Health Service (England). Use in hospitalized patients has been guided by trials and guidelines from institutions such as Mayo Clinic, Johns Hopkins Hospital, and Mount Sinai Health System.

Dosage and administration

Standard dosing regimens were established through clinical pharmacology programs run by manufacturers and regulators including Food and Drug Administration and Australian Therapeutic Goods Administration. For treatment, adults commonly receive a 75 mg twice-daily oral course for five days as advised in product monographs and hospital formularies; pediatric dosing is weight-based per pediatric protocols from centers like Children's Hospital of Philadelphia and Great Ormond Street Hospital. For prophylaxis, guidelines recommend once-daily dosing for specified durations in outbreak settings such as congregate living facilities overseen by Centers for Disease Control and Prevention field teams or military medical units in Department of Defense deployments. Dose adjustments are advised for renal impairment according to nephrology consults and renal dosing charts used in academic centers like Cleveland Clinic.

Mechanism of action

Oseltamivir is a prodrug converted to an active carboxylate that selectively inhibits viral neuraminidase, an enzyme characterized in structural studies at institutions like Max Planck Institute and Scripps Research. By binding the active site of neuraminidase, it reduces release of progeny virions from infected epithelial cells in respiratory tissues mapped in studies from universities such as Harvard University, University of Oxford, and University of Tokyo. The neuraminidase inhibition model was informed by crystallography work at facilities including Diamond Light Source and Argonne National Laboratory and by biochemical assays developed at companies like Gilead Sciences and Fujisawa Pharmaceutical.

Efficacy and clinical trials

Efficacy was assessed in randomized controlled trials conducted at academic centers and contract research organizations collaborating with manufacturers; key trials were reported in journals associated with New England Journal of Medicine, The Lancet, and JAMA. Meta-analyses by groups at Cochrane Collaboration, Imperial College London, and World Health Organization reviewed trial data, while public-access litigation releases and reviews by regulators expanded available datasets. Trials showed reductions in symptom duration in outpatient populations enrolled at clinics affiliated with University of California, San Francisco, Karolinska Institutet, and Boston Medical Center, with variable evidence for reductions in complications such as otitis media documented in pediatric studies at Children's Hospital Los Angeles.

Side effects and safety

Safety assessments were reported by pharmacovigilance programs at agencies including European Medicines Agency and Pharmaceuticals and Medical Devices Agency of Japan, and in post-marketing surveillance coordinated with bodies such as Vaccine Adverse Event Reporting System. Common adverse effects include gastrointestinal symptoms identified in clinical trials sponsored by manufacturers and academic partners; neuropsychiatric events were reported in case series from hospitals including Tokyo Medical University Hospital and investigated by regulatory safety committees. Risk-benefit evaluations in special populations, such as patients treated in oncology units at MD Anderson Cancer Center or transplant services at UCSF Medical Center, involve specialist guidelines and institutional review boards.

Pharmacology and metabolism

Oseltamivir phosphate is rapidly absorbed after oral administration and converted by hepatic and plasma esterases to the active oseltamivir carboxylate, with pharmacokinetic characterization performed in studies at Massachusetts General Hospital and by industry clinical pharmacology groups. The active metabolite is eliminated primarily by renal excretion; dose adjustments are recommended based on creatinine clearance measurements used in nephrology services and pharmacokinetic modeling from research groups at University of Toronto and University of Melbourne. Drug interaction assessments involved cytochrome P450 research at laboratories such as University of Cambridge and interactions with concomitant antiviral agents were studied in collaborative trials with centers like Fred Hutchinson Cancer Center.

History and regulatory status

The development program involved collaborations between institutions including Roche, Gilead Sciences, and research groups at universities such as University of Freiburg and Georgetown University. Regulatory approvals were granted by agencies including the Food and Drug Administration and European Medicines Agency after submission of clinical dossiers; emergency use and stockpiling decisions were made during the 2009 flu pandemic by governments and international organizations such as World Health Organization and European Commission. Controversies over trial data release, procurement policies, and pandemic preparedness involved parliamentary inquiries in jurisdictions like United Kingdom and litigation in courts including United States District Court. Ongoing surveillance and guideline updates continue via advisory committees and public health institutions such as Advisory Committee on Immunization Practices, Public Health England, and national ministries of health.

Category:Antiviral drugs